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Objective: The aim of this study was to evaluate efficacy, reasons for switching and drug 
survival of TNF-α inhibitors (TNFi-s) used as first and second line drugs in ankylosing 
spondylitis (AS). 
Methods: Data of patients suffering from AS and treated with at least one TNFi between 
November 2005 and November 2013 were extracted retrospectively from the database of one 
clinical center. Beside demographic data, the disease activity measured by BASDAI, the 
response rates (BASDAI50), reasons for switching and survival curves of TNFi-s were 
analyzed in general and in subgroups of patients treated with each of the available TNFi-s. 
The reasons for switching were defined as inefficacy, side effect of the given drug, patient’s 
request, and occurence of extra-articular manifestations.  
Results: Altogether 175 patients were on TNFi and 77 of them received at least 2 TNFi-s. The 
patients’ age at the initiation of the first TNFi was higher among switchers compared to non-
switchers (42.5±12.6 vs 38.8±11.2 years, p=0.049), otherwise gender, disease duration and 
initial disease activity had no influence on the risk of switching. The decrease of BASDAI 
was similar among non-switchers and switchers either using the first or second TNFi, but the 
response rates to the first and second TNFi were worse in switchers than in non-switchers. 
Following the failure of first TNFi, the retention on therapy was unfavourable, especially in 
patients on infliximab after one year of treatment. The main reason for switching from the 
first drug was inefficacy. The frequency of side effects that led to switching was higher in the 
infliximab group than in patiets treated with other agents. 
Conclusion: Although the retention rate to a second line TNFi was somewhat worse than that 
to the first line TNFi, switching of TNFi-s is a good therapeutic option is AS patients who 
failed to respond to the first TNFi. 
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 Introduction 
During the last decade, TNF-α inhibitors (TNFi-s) have revolutionized the treatment of 
ankylosing spondylitis (AS) patients who failed to respond to non-steroidal anti- 
inflammatory drugs (NSAIDs) and physical therapy. According to the meta-analysis of 
randomized-controlled trials (RCTs), it became evident that all available TNFi-s 
(adalimumab, etanercept, infliximab and golimumab) exert similar effects on signs and 
symptoms of the axial components of the disease (1-5). 
The use of TNFi-s in patients with AS is regulated by the ASAS (Assessment in 
SpondyloArthritis international Society) recommendations which usually serves as a basis for 
national protocols. On the basis of ASAS guideline, those AS patients are eligible for TNFi 
therapy who has active disease as determined by BASDAI (Bath Ankylosing Spondylitis 
Disease Activity Index) and do not respond to at least two NSAIDs (6). Although the 
ASAS/European League Against Rheumatism (EULAR) recommendation clearly states that 
there are no differences in efficacy among the TNFi-s on the axial and articular/entheseal 
disease manifestations (7), it has been documented in several clinical trials that the anti-TNF 
monoclonal antibodies (adalimumab, infliximab and golimumab) can be used successfully in 
the treatment of most common extra-articular manifestations of the disease, while etanercept 
has milder effect on uveitis and inflammatory bowel diseases (8;9). According to these 
observations the difference in gastrointestinal efficacy of each TNFi-s is suggested to be taken 
into account by ASAS/EULAR guidelines (7), but beyond this aspect there are no therapeutic 
recommendations how to choose between TNFis or how to switch between these agents.  
Biological therapy provides significant improvement in disease activity, functional capacity 
and disease-related quality of life for most of AS patients in a long term period, even after an 
8 year-long continuous treatment (10). However, some of the patients may not respond 
properly to the initial TNFi and their symptoms worsen over time. Another proportion of 
patients experience side effects related to the drug which interfere the continuation of the 
treatment. As the TNFi-s are structurally different and they have different mechanism of 
action, an unsuccessful treatment with a drug does not preclude response to another one (11).  
The efficacy of switching between TNFi-s in AS and axial spondyloarthritis (SpA) has been 
evaluated in a limited number of large studies. In the RAPID-axSpA trial, less than 40% of 
patients could be successfully treated with a TNFi for a period more than 3 months before 
certolizumab-pegol treatment, if the reason of discontinuation was other than primary failure. 
The subgroup analysis of trial has not been published yet (12). In an open label trial, 26.1% of 
1250 AS patients treated with adalimumab had previously received etanercept and/or 
infliximab. Among patients used adalimumab as second line treatment worse response rates of 
BASDAI50, ASAS40 and partial remission could be observed than in patients treated with 
this drug as first line choice (13).  
The Danish and Norwegian national registries provide data of AS patients who switched to 
another biologic (14;15). In the DANBIO registry data of 432 patients that switched to a 
second and those of 137 patients switched to a third TNFi were analyzed and compared to 
data of 1004 non-switchers. It was concluded that response rates and drug survival were lower 
among switchers. The NOR–DMARD register evaluated the effectiveness of second TNFi-s 
among 77 switchers with AS and switching to a second TNFi was found to be a useful way in 
daily practice, although it results in lower overall effectiveness. 
As available data on efficacy of primary and subsequent TNFi therapy and predictive factors 
of effectiveness of the second choice drug are controversial, and few systematic analyses of 
reasons of switching and treatment responses of each TNFi-s among switchers and non-
switchers have been published, we wished to assess these issues under real-world 
circumstances. In the present study the reasons for switches, the effect of TNFi-s on disease 
activity among switchers and non-switchers, the predictive factors of effectiveness and drug 
survival were analysed in a relatively large number of AS patients treated in one 
rheumatology center.  
 
Patients and methods 
All AS patients treated with any TNFi-s at the Department of Rheumatology, University of 
Debrecen, Hungary between November 1, 2005 and November 30, 2013 were included in this 
study. A total of 175 AS patients, as defined by modified New York criteria were included in 
the study. Ninety-eight patients remained on the first line TNFi, while 77 of them were treated 
with at least two different biologics. First and subsequent therapies were one of the following 
four drugs: adalimumab, etanercept, golimumab and infliximab. These biologics were used 
according to the standard clinical practice: adalimumab 40 mg every second week 
subcutaneously (sc); etanercept 50 mg weekly sc; golimumab 50 mg monthly sc; and 
infliximab 5 mg/kg every eight weeks intravenously (iv) after induction doses at baseline, and 
after 2 and 6 weeks. All biologics were administered according to the Hungarian national 
protocol which is similar to the ASAS recommendations (6;16). Before TNFi therapy all 
patients had active disease defined by elevated BASDAI (≥4 on a visual analog scale, 0-10) 
despite prior treatment with at least 2 different NSAIDs or at least one NSAID if it was not 
tolerated or without prior NSAID treatment if it was contraindicated.  
The reasons for switches between TNFi-s were inadequate response to the drug as defined by 
elevation of BASDAI at two subsequent controls to 4 or above at 3 months after the initiation. 
The other reasons for stopping therapy and/or switches were side effects or patient’s request 
(e.g. request to change from iv to sc administration or planned pregnancy) or development of 
a new extra-articular manifestation. The reasons for switching were classified into 
prespecified categories: primary and secondary inefficacy (IE), side effect of the drug (SE), 
appearrance of extra-articular manifestation required switching (EA) and patient’s request 
(PR).  There were 3 patients who were treated further in another rheumatology center and it 
was impossible to get accurate informations about their disease, so they were excluded from 
further data analysis.       
The study design was a retrospective, one-center, observational analysis with assessments 
performed at baseline, and after 3, 6 and 12 months. The demographics of patients, date of 
diagnosis, start and stop date of each biologic therapy, the BASDAI at baseline and during 
treatment, response rates (BASDAI50) and reasons for switches were collected.  
We used the product limit method of Kaplan and Meier to estimate how long patient remained 
on a given biological drug. Drug survival was calculated as the number of months between 
the dates of first dose and last dose of the same drug. As adalimumab and especially 
golimumab were approved later for treatment AS than infliximab and etanercept the follow-
up periods were shorter in the case of aforementioned drugs.  
Data were analyzed using the IBM SPSS 20 statistical software.  Baseline demographics and 
diseases characteristics were analyzed with frequency calculation and descriptive statistics 
(chi square test, independent sample t test and Mann-Whitney test). The estimated drug 
survivals were calculated by Kaplan-Meier method. We used log-rank test to compare the 





Of the 175 AS patients who treated with any of the TNFi-s, 77 switched to a second and 11 
out of 77 to a third TNFi. Infliximab was the most commonly administered TNFi as first 
choice treatment. Out of 68 patients treated with this drug, 39 patients (57%) required switch 
to a seccond TNFi. These ratios were 10 out of 40 (25%) with adalimumab, 25 out of 58 
(43%) with etanercept and 3 out of 9 (33%) with golimumab, respectively. As third choice 
treatment, golimumab was used most often (6 patients) followed by adalimumab and 
etanercept (3 and 2 patients, respectively) (figure 1.).  
The baseline characteristics for patients treated with and without switching of TNFi-s are 
summarized in table 1. Significant differences were found between the two groups with 
regards to age of patients at the initiation of the first TNFi. Patients who switched TNFi 
during the course of their disease were older compared to non-switchers (42.5±12.6 v. 
38.8±11.2; p=0.049).   
Effectiveness of treatment 
The effect of treatment assessed by BASDAI was followed during the first 12 months. The 
improvement of BASDAI to the first choice drug was similarly significant among switchers 
and non-switchers (at start of treatment: 7.06±1.30 and 7.11±1.18; p=0.468, at month 3: 
2.38±1.21 and 3.15±1.98; p=0.058 among non-switchers and switchers, respectively).  
Although a worsening of BASDAI could be seen among switchers used golimumab between 
6th and 12th months, but it can be explained by increase of this value of a single patient. As 
the number of patients on golimumab was rather small compared to other treatment groups, 
this result is difficult to interpret. The data of patients came through 2 switches were not 
analyzed because of low number of patients belonging to each treatment groups.  Analyzing 
BASDAI values after switching all of the second TNFi-s led to similar improvements between 
0 and 3 months as it could be observed by using first TNFi (5.44±2.40 and 2.16±1.58, 
respectively), although the initial BASDAI values before switching were lower than in TNFi 
naïve patients, as a significant proportion of them switched due to side effect to the first drug 
and it was associated with low BASDAI value before starting the second TNFi. However, 
after this period a significant worsening of BASDAI could be detected in 8 patients treated 
with infliximab and this unfavourable change continued between the 6th and 12th months 
(figure 2.).  
The response rates to the first TNFi measured by BASDAI50 were generally inferior in 77 
switchers than in 98 non-switchers (at 3rd, 6th and 12th months 72.3%, 74.6%, 70.8% in non-
switchers and 56.0%, 51.0% and 54.3% in switchers, repectively).  The treatment with the 
second TNFi after 3, 6 and 12 months achieved similar BASDAI50 responses (51.6%, 50.9% 
and 46.9%, respectively) than those of among switchers to the first TNFi.   
Reasons for switching 
The reason for switching to a second TNFi was IE in most cases (42 patients out of 77). 
Switching was necessary due to any type of AEs in 23 patients. These AEs most often 
included infusion reactions in patients treated with infliximab and localised/generalised 
reactions to sc injections. The patient’s request was the cause of switching in 5 cases resulted 
in 4 switches in the infliximab and one in the adalimumab group. During TNFi therapy, 6 
extra-articular manifestations (3 uveitis flares, 2 inflammatory bowel diseases and one 
psoriasis) developed that required switching. Most of these patients were treated with 
etanercept and after occurrence of these manifestations they were switched to any of the anti-
TNF monoclonal antibodies which can be used more effectively in these comorbidities. While 
the most common reasons for switching were IE in the adalimumab, etanercept and 
golimumab groups, the ratio of IE and SE necessitated stop of first choice drug were almost 
equal among infliximab treated patients (table 2).          
Drug survival 
In our study, the overall survival times of first line TNFi-s was better than it could be 
observed with second line drugs (62.88 months (CI 95%: 56.67-69.09) and 39.29 months (CI 
95%: 31.29-47.03), p=0.05, respectively).  Comparing the various TNFi-s used as first line 
drugs, the longest retention times were observed with adalimumab (66.6 months (CI 95%: 
56.84-76.50)) and etanercept (66.8 months (CI 95%: 56.20-77.56)). The mean drug survival 
times for infliximab and golimumab were 52.5 (CI 95%: 42.82-62.26) and 33.4 (CI 95%: 
23.14-43.66), respectively, however we should note that golimumab received European 
approval for treatment AS much later than the other TNFi-s. When these drugs were 
administered as second line treatment, the drug retention times were 41.2 (CI 95%: 30.53-
52.00) months with adalimumab, 31.3 (CI 95%: 10.42-52.29) months with etanercept, 36.6 
(CI 95% 29.20-44.11) months with golimumab and 9.3 (CI 95%: 3.36-15.24) months with 
infliximab.  
Based on Figure 3. there is an impression that retention to first line therapy was superior 
among patients treated with adalimumab and etanercept compared with infliximab users. 
Among patients used infliximab as first line drug a sharp decrease could be observed in drug 
survival between 13th and 17th months of treatment (at month 13: 84.5%, at month 17: 
71.0%). Due to the above mentioned reason, the retention curve of golimumab is shorter than 
those of other drugs. Although the number of treated patients in each groups are rather low 
after switching, the best drug adherence could be experienced in golimumab, the worst one in 
the influximab-treated patients. 
  
Discussion 
According to our one-center observational study, almost half of the AS patients treated with 
TNFi switch their firstly used drug to another one, while only a small proportion of them 
would switch to a third TNFi during a follow-up period of up to 8 years. Switches could be 
detected more frequently among older patients. Although the efficacy of first and second 
TNFi-s seemed to be similar, as no differences could be measured between each TNFi-s by 
decrease of BASDAI values, the retention rate of infliximab was worse than those of other 
TNFi-s. The most common reasons for switching were the loss of effect among adalimumab, 
etanercept and golimumab treated patients, while in infliximab treated patients the ratio of 
inefficacy and side effect led to switching were almost equal.  
The effectiveness and safety of biological drugs in AS have been proved by RCTs. Cost-
effectiveness models with input from RCTs, however, represent results obtained under 
rigorous experimental conditions. The precision and applicability of these data to other 
settings may be argued. In the real world of prescription and use, drugs are applied in a 
broader population, use of concomittant medicines may vary, the same as patients’ 
compliance and their expectations for health (17). Moreover, biological drug sequences that 
do indeed occur in everyday practice (e.g., switch to a third or fourth drug, return back to a 
previous one) have never been studied in RCTs. These discrepancies may alter both 
effectiveness and safety, as well as drug survival rates. Thus alongside the growing body of 
actual practice data with biologicals there is an increasing need to use registry data in cost-
effectiveness analyses that reinforces their value. Moreover, the demand for health technology 
assessments (HTA) based on local data is getting higher and higher (18-22). 
National registries and observational studies have proven that the frequencies of switches 
between biologics are higher among patients with rheumatoid arthritis and psoriatic arthritis 
than in AS, even though patients with peripheral arthritis are usually treated with disease 
modifying antirheumatic drugs (DMARD), which, at least theoretically, should postpone the 
loss of effect.  The ratio of AS patients switched to a second TNFi out of TNF naive patients 
were 15% and 30 % in Norwegian and Danish nationwide registries in a 8-9 years of follow-
up. Similar switching frequencies (13-15%) have been published in observational studies 
included around 100 AS patients (23;24). In contrast, in our retrospective study much higher 
frequency of switching could be detected. It can be explained by the strict Hungarian 
regulation of monitoring of effectiveness during the course of treatment. According to this 
regulation the TNFi is considered to be effective if the BASDAI value decrease at least 50% 
or 2 units between 0 and 3rd months of treatment and BASDAI do not exceed the value 
observed at months 3 at 2 following visits. Thus, a relatively large proportion of patients 
underwent switching despite only moderate worsening of symptoms.  
We found that disease activity, measured by BASDAI decreased significantly both in group 
of non-switchers and switchers under the treatment of first line TNFi-s, but among switchers 
this improvement was somehow less. On one hand, the primary lack of efficacy and early 
switching due to loss of efficacy (ie. before the end of 1 year follow-up) may cause this 
difference, but on the other hand, the milder effect of first line drug before switching can also 
influence this result. As in our study only 5 out of 77 switchers were primary non-responders 
to TNF-i, we can suppose that the decrease of BASDAI may be in connection with the risk of 
subsequent switching.  
In our cohort, the age of the switchers was significantly higher than those of non-switchers at 
start of first TNFi. No differences could be demonstrated in initial BASDAI values and 
disease duration. Switchers were more frequently women than men, but this difference was 
not statistically significant. This finding seems to be logical as the TNFi-s are able to decrease 
inflammation which is typical in earlier stage of the disease and presumably in younger age, 
but this difference was not reflected by the disease duration. In national registries the higher 
median values of initial BASDAI were congruent, but the higher percentage of women, 
shorter disease and symptom duration, higher diasease activity and functional indices were 
found among switchers compared to non-switchers (14;15).  
Although the national registries and observational studies included relatively large number of 
patients undergoing TNFi switching, no data are available about outcome of treatment with 
each TNFi-s, which is in connection with survival rate of these drugs. It is obvious, that our 
study is underpowered due to the limited number of switches and the non-randomised study 
design, but noticeable results were obtained with respect to reasons for stopping of each 
biological agent. In general, inefficacy was the most common cause of switching of primary 
treatment, which usually occured at least 3 months after the start of treatment, so it was 
secondary loss of effect. However, in the infliximab group, the ratio of side effects that led to 
switching was higher than in the other three groups. Most of these side effects were mild or 
moderate infusion reactions, which were sometimes overweighed and resulted in earlier 
switches than it would have been necessary. But these side effects, and of course the 
secondary loss of efficacy, can be explained by the unique chemical structure of this drug 
(25). The chimeric monoclonal antobody induces production of anti-drug antibodies more 
intensively than the humanised ones (adalimumab and golimumab) and the receptor fusion 
protein etanercept. It was published recently, that in patients with spondyloarthropathies anti-
drug antibodies could be detected in 25.9% of patients, most frequently in infliximab treated 
ones (81.8%) compared to those ones treated with adalimumab (18.2%) and etanercept (0%) 
(26). As these anti-drug antibodies are responsible for treatment failures at least in some of 
the cases, it may support the validity of our results. Moreover, in our study a sharp decrease 
were observed in retention on infliximab between 13th and 17th months of treatment. These 
results agree with the above mentioned study which could detect the appearance of anti-drug 
antibodies mainly at the end of first year of the treatment (12.89±5.92 months). In a meta-
analysis that evaluated the presence and effects of anti-drug antibodies in patients with 
different inflammatory diseases, such as rheumatoid arthritis, spondyloarthropathies and 
inflammatory bowel diseases, the drug response was reduced if anti-drug antibodies could be 
detected in the sera of patients. Among different diseases the effect of anti-drug antibody 
positivity on TNFi responses was more pronounced in AS and spondyloarthropathies than in 
other diseases (27). As concomittant treatment with methotrexate or other immunosuppressive 
drugs reduces the production of these antibodies, and as in axial form of 
spondyloarthropathies these type of drugs are usually not administered, it may highlight the 
necessity of determination of anti-drug antibodies in cases of loss of efficacy in AS, which 
may give further support for the decision of switching. 
Among switchers, the effect of firstly and secondly used TNFi-s on disease activity measured 
by BASDAI and the response rates measured by BASDAI50 were similar during the one-year 
follow-up period in our retrospective analysis. Although the rate of patients achieving 
BASDAI50 was somewhat higher than the values published recently by other investigators 
(14;15), our findings are comparable with those results. However, the drug survival times of 
TNFi-s used second-line were worse than in first line treatment. These data suggest that 
switching to another TNFi may be a useful option and in general, the response is not worse, 
however the risk of switching is higher over time.  
Limitations of this study include the retrospective, one-center design, lack of unequivocal 
definitions for switching, and short follow-up to detect the patients’ responses to the 
treatment. However, we investigated a reasonably large population of patients treated in real-
life setting, which allowed us to analyze efficacy, side-effects and survivals of each TNFi-s 
among patients with AS. In conclusion, our data indicate that switching between TNFi-s is a 
good therapeutic option if the patient failed to respond or intolerant to the formerly used 
agent, but the humanized monoclonal antibodies or receptor fusion protein should be 
preferred. 
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Legends to the figures 
 
Figure 1. Patterns of treatment courses of ankylosing spondylitis patients. Numbers show the 
number of patients treated with each TNF blockeres as first choice drugs and after switching. 
Table 1. Baseline characteristics of patients remained on initiating TNFi treatment and 
switched to another one.  
Figure 2. Mean BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) values 
among patients remained on firstly used TNF blockers (A) till the end of observation, and 
among those ones who switched to a second drug before (B) and after (C) switching.  
Table 2.  Reasons of switching of fist choice TNFi among ptients treated with adalimumab, 
etanercept, golimumab and infliximab.  
Figure 3. Kaplan-Meier drug survival curves of adalimumab, etanercept, golimumab and 
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